EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes

David R Riley iD, Hani Essa, Philip Austin iD, Frank Preston, Isatu Kargbo, Gema Hernández Ibarburu, Ramandeep Ghuman, Daniel J Cuthbertson, Gregory Y H Lip iD, Uazman Alam

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von David R Riley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases, Symporters. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the relationship of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i + GLP‐1RA) with 5‐year risk of all‐cause mortality, hospitalization and cardiovascular/macrovascular disease in people with type 2 diabetes. Materials and Methods Retrospective cohort analysis of 2.2 million people with type 2 diabetes receiving insulin across 85 health care organizations using a global federated health research network. Three intervention cohorts (SGLT2i, GLP‐1RA and SGLT2i + GLP‐1RA) were compared against a control cohort (no SGLT2i/GLP‐1RA). Propensity score matching for age, ischaemic heart disease, sex, hypertension, chronic kidney disease, heart failure and glycated haemoglobin was used to balance cohorts 1:1 (SGLT2i, n = 143 600; GLP‐1RA, n = 186 841; SGLT‐2i + GLP‐1RA, n = 108 504). A sub‐analysis comparing combination and monotherapy cohorts was also performed.

Results

The intervention cohorts showed a reduced hazard ratio (HR, 95% confidence interval) over 5 years compared with the control cohort for all‐cause mortality (SGLT2i 0.49, 0.48‐0.50; GLP‐1RA 0.47, 0.46‐0.48; combination 0.25, 0.24‐0.26), hospitalization (0.73, 0.72‐0.74; 0.69, 0.68‐0.69; 0.60, 0.59‐0.61) and acute myocardial infarct (0.75, 0.72‐0.78; 0.70, 0.68‐0.73; 0.63, 0.60‐0.66), respectively. All other outcomes showed a significant risk reduction in favour of the intervention cohorts. The sub‐analysis showed a significant risk reduction in all‐cause mortality for combination therapy versus SGLT2i (0.53, 0.50‐0.55) and GLP‐1RA (0.56, 0.54‐0.59).

Conclusions

SGLT2i, GLP‐1RAs or combination therapy confers mortality and cardiovascular protection in people with type 2 diabetes over 5 years. Combination therapy was associated with the greatest risk reduction in all‐cause mortality versus a propensity matched control cohort. In addition, combination therapy offers a reduction in 5‐year all‐cause mortality when compared directly against either monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesSymportersHumansHypoglycemic AgentsRetrospective StudiesGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney diseaseglucagon-like peptide-1 receptor agonistshospitalizationmortalitysodium-glucose cotransporter 2 inhibitorstype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSymportersGlucoseSodiumGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK.
  • Department of Medicine, University Hospital Aintree, Liverpool University NHS Foundation Trust, Liverpool, UK.
  • Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
  • TriNetX LLC, Cambridge, Massachusetts, USA.
  • Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
  • Pain Research Institute, University of Liverpool and Liverpool University Hospital NHS Foundation Trust, Liverpool, UK.

ORCID-Profile: David R Riley, Philip Austin, Gregory Y H Lip

Zitieren

APA

Riley, D. R., Essa, H., Austin, P., Preston, F., Kargbo, I., Ibarburu, G. H., Ghuman, R., Cuthbertson, D. J., Lip, G. Y. H., & Alam, U. (2023). All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15185

Vancouver

Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, et al. All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15185

BibTeX
@article{Riley2023,
  author = {Riley, David R and Essa, Hani and Austin, Philip and Preston, Frank and Kargbo, Isatu and Ibarburu, Gema Hernández and Ghuman, Ramandeep and Cuthbertson, Daniel J and Lip, Gregory Y H and Alam, Uazman},
  title = {All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination therapy in people with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15185}
}
Kostenlos starten →